BridgeMD
New treatment option for Pancreatic Cancer
Official title Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
ClinicalTrials.gov ID: NCT06649474
What this study is testing
What is assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy?
assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy is an investigational medicine, being studied as a potential treatment for pancreatic cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ECOG WHO Performance status = 0 or 1
- Signed and dated informed consent
- Patients with histological diagnosis of oesogastric or pancreatic adenocarcinoma
- Resectable tumors
- Patients able to have a laparoscopy
You likely can't join if
- Histology other than adenocarcinoma
- Metastatic disease
- History of previous treatment with oxaliplatine
- History of systemic chemotherapy administration within 5 years prior to inclusion,
- Patient with an non balanced progressive condition/disease (liver failure, renal failure (creatinine clearance \<30mL/min), respiratory failure...
- Patient on curative dose anticoagulant,
See the full eligibility criteria
- ECOG WHO Performance status = 0 or 1
- Signed and dated informed consent
- Patients with histological diagnosis of oesogastric or pancreatic adenocarcinoma
- Resectable tumors
- Patients able to have a laparoscopy
- In case of absence of peritoneal invasion on the laparoscopy, patient candidate to a chemotherapy schedule by FLOT or FOLFOX in perioperative setting for oesogastric adenocarcinoma, or FOLFIRINOX in perioperative...
- Registration in a national health care system (CMU included)
- Patient speak and understand the french
- Histology other than adenocarcinoma
- Metastatic disease
- History of previous treatment with oxaliplatine
- History of systemic chemotherapy administration within 5 years prior to inclusion,
- Patient with an non balanced progressive condition/disease (liver failure, renal failure (creatinine clearance \<30mL/min), respiratory failure, congestive heart failure, myocardial infarction in the last 6 months...
- Patient on curative dose anticoagulant,
- Patient with complete dihydropyrimidine dehydrogenase deficiency (Uracilemia ≥ 150 ng/ml),
- Patient not operable for the pathology concerned,
- Pregnant or breastfeeding woman, woman of childbearing age who has not performed a pregnancy test before the procedure,
- Patient with legal incapacity (person deprived of liberty or under curatorship, stutorship, safeguard of justice),
- Patient who, for psychiatric, social, family or geographical reasons, cannot be followed and/or comply with the requirements of the study,,
- Discovery of peritoneal invasion during the peritoneal exploratory of the laparoscopy
The study team makes the final eligibility decision.
Where it's taking place
- Clermont-Ferrand, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Clermont-Ferrand, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.